Ovarian responses to menopausal gonadotropins in groups of patients with differing basal growth hormone levels.
OBJECTIVE
To investigate the relationship between endogenous serum levels of human growth hormone (hGH) and ovarian response to human menopausal gonadotropins (hMG).


METHODS
Retrospective analysis of patient response to hMG.


METHODS
Center for assisted reproductive technology.


METHODS
Eighty women who had undergone controlled ovarian hyperstimulation with hMG. Basal levels of hGH in sera from 40 of these patients were less than 5.0 microIU/mL (low hGH), values for the remaining 40 were greater than 5.0 microIU/mL (high hGH). Levels of hGH in day 2 sera were analyzed against numbers of oocytes recovered in an additional 182 patients.


METHODS
Serum estradiol (E2) levels and numbers of oocytes recovered at oocyte pick-up.


RESULTS
Average (+/- SE) levels of hGH in sera of high-hGH and low-hGH patients were 10.2 +/- 0.6 and 2.47 +/- 0.3 microIU/mL, respectively (P less than 0.05). Respective peripheral levels of insulin-like growth factor-I were 105.3 +/- 2.9 and 97.2 +/- 2.8 ng/mL. Levels of E2 in serum of high-hGH patients exceeded respective (P less than 0.05) low-hGH values throughout folliculogenesis, and more oocytes were recovered from high-hGH patients (8.1 +/- 0.9 versus 4.7 +/- 0.5 for low-hGH patients; P less than 0.05). Serum progesterone values did not differ. Higher day 2 hGH levels were associated with higher numbers of oocytes recovered after controlled ovarian hyperstimulation.


CONCLUSIONS
The present findings indicate that endogenous hGH may augment gonadotropins during follicle recruitment and during multiple folliculogenesis in women. The phase of maximum ovarian sensitivity to hGH/gonadotropin synergism and the nature of synergism remain unclear.
Stone
B A
BA
Reproductive Endocrine Laboratory, Institute for Reproductive Research, Los Angeles, California 90017.
Marrs
R P
RP
D000328:Adult; D004958:Estradiol / Q000097:blood; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008183:Luteal Phase / Q000502:physiology; D008596:Menotropins / Q000494:pharmacology*; D016471:Ovarian Hyperstimulation Syndrome / Q000503:physiopathology; D010053:Ovary / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D011374:Progesterone / Q000097:blood; D012189:Retrospective Studies
D011374:Progesterone; D004958:Estradiol; D008596:Menotropins; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone